You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, May 2019
|
| DOI | 10.1186/s40425-019-0615-z |
| Pubmed ID | |
| Authors |
Moshe C. Ornstein, Laura S. Wood, Brian P. Hobbs, Kimberly D. Allman, Allison Martin, Michael Bevan, Timothy D. Gilligan, Jorge A. Garcia, Brian I. Rini |
X Demographics
The data shown below were collected from the profiles of 32 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 16 | 50% |
| Japan | 3 | 9% |
| Canada | 2 | 6% |
| Switzerland | 1 | 3% |
| Brazil | 1 | 3% |
| Spain | 1 | 3% |
| Norway | 1 | 3% |
| Germany | 1 | 3% |
| Unknown | 6 | 19% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 44% |
| Scientists | 11 | 34% |
| Practitioners (doctors, other healthcare professionals) | 6 | 19% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 73 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 73 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 12% |
| Student > Bachelor | 6 | 8% |
| Lecturer | 3 | 4% |
| Student > Doctoral Student | 3 | 4% |
| Other | 3 | 4% |
| Other | 11 | 15% |
| Unknown | 38 | 52% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Nursing and Health Professions | 4 | 5% |
| Biochemistry, Genetics and Molecular Biology | 4 | 5% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 4 | 5% |
| Unknown | 41 | 56% |
Attention Score in Context
This research output has an Altmetric Attention Score of 18. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2019.
All research outputs
#2,004,740
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#530
of 3,424 outputs
Outputs of similar age
#43,101
of 365,330 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#16
of 70 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,424 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 365,330 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.